JP2024534157A5 - - Google Patents
Info
- Publication number
- JP2024534157A5 JP2024534157A5 JP2024513011A JP2024513011A JP2024534157A5 JP 2024534157 A5 JP2024534157 A5 JP 2024534157A5 JP 2024513011 A JP2024513011 A JP 2024513011A JP 2024513011 A JP2024513011 A JP 2024513011A JP 2024534157 A5 JP2024534157 A5 JP 2024534157A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237898P | 2021-08-27 | 2021-08-27 | |
| US63/237,898 | 2021-08-27 | ||
| PCT/US2022/075493 WO2023028575A2 (en) | 2021-08-27 | 2022-08-26 | Compounds and methods for modulating scn1a expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534157A JP2024534157A (ja) | 2024-09-18 |
| JPWO2023028575A5 JPWO2023028575A5 (https=) | 2025-09-02 |
| JP2024534157A5 true JP2024534157A5 (https=) | 2025-09-02 |
Family
ID=85322277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513011A Pending JP2024534157A (ja) | 2021-08-27 | 2022-08-26 | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240360449A1 (https=) |
| EP (1) | EP4392562A4 (https=) |
| JP (1) | JP2024534157A (https=) |
| KR (1) | KR20240049349A (https=) |
| CN (1) | CN118451183A (https=) |
| AU (1) | AU2022334739A1 (https=) |
| CA (1) | CA3230299A1 (https=) |
| IL (1) | IL310811A (https=) |
| MX (1) | MX2024002553A (https=) |
| WO (1) | WO2023028575A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| CN116334086A (zh) * | 2023-03-29 | 2023-06-27 | 广州医科大学附属第二医院 | 一种用于修复或抑制SCN1A基因异常剪接的U1-snRNA及其用途 |
| WO2025024568A1 (en) * | 2023-07-24 | 2025-01-30 | Stoke Therapeutics, Inc. | Methods for treating conditions and diseases |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001590RA (en) * | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| US20220372489A1 (en) * | 2019-06-21 | 2022-11-24 | Quralis Corporation | Ppm1a inhibitors and methods of using same |
| EP4013767A4 (en) * | 2019-08-15 | 2023-10-25 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
| BR112022010882A2 (pt) * | 2019-12-06 | 2022-10-04 | Stoke Therapeutics Inc | Oligômeros antissenso para tratamento de condições e doenças |
| WO2021174036A1 (en) * | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating scn1a expression |
-
2022
- 2022-08-26 EP EP22862285.8A patent/EP4392562A4/en active Pending
- 2022-08-26 AU AU2022334739A patent/AU2022334739A1/en active Pending
- 2022-08-26 CA CA3230299A patent/CA3230299A1/en active Pending
- 2022-08-26 KR KR1020247009728A patent/KR20240049349A/ko active Pending
- 2022-08-26 US US18/685,362 patent/US20240360449A1/en active Pending
- 2022-08-26 WO PCT/US2022/075493 patent/WO2023028575A2/en not_active Ceased
- 2022-08-26 JP JP2024513011A patent/JP2024534157A/ja active Pending
- 2022-08-26 MX MX2024002553A patent/MX2024002553A/es unknown
- 2022-08-26 IL IL310811A patent/IL310811A/en unknown
- 2022-08-26 CN CN202280065211.6A patent/CN118451183A/zh active Pending